Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Total Liabilities (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed Total Liabilities for 9 consecutive years, with $129.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Liabilities fell 4.5% to $129.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $129.4 million, a 4.5% decrease, with the full-year FY2024 number at $144.5 million, up 17.51% from a year prior.
  • Total Liabilities was $129.4 million for Q3 2025 at Denali Therapeutics, down from $139.2 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $442.6 million in Q1 2023 to a low of $115.5 million in Q2 2024.
  • A 5-year average of $270.8 million and a median of $148.7 million in 2025 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: skyrocketed 201.1% in 2021, then tumbled 71.62% in 2024.
  • Denali Therapeutics' Total Liabilities stood at $441.9 million in 2021, then decreased by 5.44% to $417.8 million in 2022, then tumbled by 70.57% to $123.0 million in 2023, then grew by 17.51% to $144.5 million in 2024, then dropped by 10.43% to $129.4 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Total Liabilities are $129.4 million (Q3 2025), $139.2 million (Q2 2025), and $148.7 million (Q1 2025).